Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. | J Drugs Dermatol;13(1): 56-61, 2014 Jan. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study.

Moore, Angela; Kempers, Steven; Murakawa, George; Weiss, Jonathan; Tauscher, Amanda; Swinyer, Leonard; Liu, Hong; Leoni, Matthew.

J Drugs Dermatol ; 13(1): 56-61, 2014 Jan.

Article in En | MEDLINE | ID: mdl-24385120

Subject(s)

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Quinoxalines / Rosacea / Adrenergic alpha-Agonists / Face Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: J Drugs Dermatol Journal subject: DERMATOLOGIA Year: 2014 Document type: Article Country of publication:

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Quinoxalines / Rosacea / Adrenergic alpha-Agonists / Face Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: J Drugs Dermatol Journal subject: DERMATOLOGIA Year: 2014 Document type: Article Country of publication: